Galactose Supplementation for the Treatment of MOGHE

Last updated: April 3, 2021
Sponsor: Hospital Ruber Internacional
Overall Status: Active - Recruiting

Phase

N/A

Condition

Epilepsy

Epilepsy (Pediatric)

Treatment

N/A

Clinical Study ID

NCT04833322
NEUROLOGIAHRI-01
  • Ages 2-20
  • All Genders

Study Summary

Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is a new entity frequently associated with refractory epilepsy and neurodevelopmental disorders. Recently, it has been associated to SLC35A2 (Solute Carrier Family 35 Member A2) brain mosaic pathogenic variants. In addition, patients with germline SLC35A2 pathogenic variants improve with galactose supplementation. Therefore, the investigators aim to elucidate whether d-galactose as an add-on treatment might improve epilepsy and developmental outcomes in patients with MOGHE.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • MOGHE diagnosis at histopathological examination of the epilepsy surgery tissue.
  • Epilepsy refractoriness or ongoing epileptiform activity at EEG.

Exclusion

Exclusion Criteria:

  • Allergy to galactose or supplement components.

Study Design

Total Participants: 8
Study Start date:
January 15, 2021
Estimated Completion Date:
October 01, 2021

Connect with a study center

  • Hospital Ruber Internacional

    Madrid, Madrid, Comunidad De 28034
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.